Levomepromazine

Summary

Levomepromazine (CHEMBL1764) is an approved small-molecule phenothiazine antipsychotic drug (ATC N05AA02); indicated across 5 conditions including psychotic disorder and anxiety.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05AA02
• Indications: 5 conditions
• Clinical trials: 2
• Chemistry: 328.5 Da · C19H24N2OS

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1764
Name	Levomepromazine
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	72287
ChEBI	CHEBI:6838
ATC	N05AA02
Molecular formula	C19H24N2OS
Molecular weight	328.5
InChIKey	VRQVVMDWGGWHTJ-CQSZACIVSA-N

SMILES: C[C@@H](CN1C2=CC=CC=C2SC3=C1C=C(C=C3)OC)CN(C)C

IUPAC name: (2R)-3-(2-methoxyphenothiazin-10-yl)-N,N,2-trimethylpropan-1-amine

ChEBI definition: A member of the class of phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively.

Pharmacological roles (ChEBI): phenothiazine antipsychotic drug, dopaminergic antagonist, serotonergic antagonist, cholinergic antagonist, non-narcotic analgesic, EC 3.4.21.26 (prolyl oligopeptidase) inhibitor, anticoronaviral agent.

Also known as: CL 36467, CL 39743, CL-36467, CL-39743, Levomepromazina, Levomepromazine, Levoprome, Methotrimeprazine, N05AA02, Neozine, Nirvan, NSC-226516

Parent form; salt/anhydrous children: CHEMBL1725730, CHEMBL2104973

Patent coverage: 2,165 distinct patent families (7,892 SureChEMBL compound mentions), from 3 matched compound structure(s). One matched structure accounts for 7,710 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 12 (assay-derived). Sample: Pleiotropic ABC efflux transporter of multiple drugs, Alpha-2A adrenergic receptor, D(1A) dopamine receptor, Thromboxane A2 receptor, Muscarinic acetylcholine receptor M2, 5-hydroxytryptamine receptor 1A, Muscarinic acetylcholine receptor M1, Prostaglandin G/H synthase 1, Alpha-1A adrenergic receptor, Mu-type opioid receptor, D(3) dopamine receptor, Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

ChEMBL activities: 8 potent at pChembl ≥ 5 of 12 total. Top 100 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
ADRA1A	7.85	AC50	14.1	nM	CHEMBL_ACT_25218996
DRD3	7.72	AC50	19	nM	CHEMBL_ACT_25194689
DRD1	6.91	AC50	122.9	nM	CHEMBL_ACT_25115381
CHRM1	6.48	AC50	331.4	nM	CHEMBL_ACT_25210359
CHRM2	5.77	AC50	1683	nM	CHEMBL_ACT_25195907
ADRA2A	5.68	AC50	2106	nM	CHEMBL_ACT_25156600
HTR1A	5.55	AC50	2842	nM	CHEMBL_ACT_25165195
P33302	5.02	IC50	9600	nM	CHEMBL_ACT_5306672

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
psychotic disorder	4	MONDO:0005485	EFO:0005407

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
anxiety	3	MONDO:0011918	EFO:0005230
dementia	3	MONDO:0001627	HP:0000726
depressive disorder	3	MONDO:0002050	MONDO:0002050

1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 2.

Phase distribution

Phase	Trials
PHASE3	1
Not specified	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02374567	PHASE3	TERMINATED	Pharmacovigilance in Gerontopsychiatric Patients
NCT03019887	Not specified	COMPLETED	Correlation Between Cognitive Function and Relapse of Schizophrenia Regarding Dose Reduction

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).